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Genetic variation in 117 
myelination-related genes in 
schizophrenia: Replication of 
association to lipid biosynthesis 
genes
Tomasz Stokowy1,2, Tatiana Polushina1,2, Ida E. Sønderby3,4, Robert Karlsson  5, Sudheer 
Giddaluru1,2, Stephanie Le Hellard1,2, Sarah E. Bergen5, Patrick F. Sullivan5,6, Ole A. 
Andreassen4,7, Srdjan Djurovic1,3, Christina M. Hultman5 & Vidar M. Steen  1,2
Schizophrenia is a serious psychotic disorder with high heritability. Several common genetic variants, 
rare copy number variants and ultra-rare gene-disrupting mutations have been linked to disease 
susceptibility, but there is still a large gap between the estimated and explained heritability. Since 
several studies have indicated brain myelination abnormalities in schizophrenia, we aimed to examine 
whether variants in myelination-related genes could be associated with risk for schizophrenia. We 
established a set of 117 myelination genes by database searches and manual curation. We used a 
combination of GWAS (SCZ_N = 35,476; CTRL_N = 46,839), exome chip (SCZ_N = 269; CTRL_N = 336) 
and exome sequencing data (SCZ_N = 2,527; CTRL_N = 2,536) from schizophrenia cases and healthy 
controls to examine common and rare variants. We found that a subset of lipid-related genes was 
nominally associated with schizophrenia (p = 0.037), but this signal did not survive multiple testing 
correction (FWER = 0.16) and was mainly driven by the SREBF1 and SREBF2 genes that have already 
been linked to schizophrenia. Further analysis demonstrated that the lowest nominal p-values were 
p = 0.0018 for a single common variant (rs8539) and p = 0.012 for burden of rare variants (LRP1 
gene), but none of them survived multiple testing correction. Our findings suggest that variation in 
myelination-related genes is not a major risk factor for schizophrenia.
Schizophrenia (SCZ) is a serious psychotic disorder with estimated high heritability (0.64–0.81)1–3. For a long 
time, the nature of this genetic susceptibility was not known, but this situation has changed markedly during the 
last 10 years, especially due to the success of the Psychiatric Genetics Consortium (PGC). So far, 108 gene loci 
have been significantly associated with SCZ by genome-wide association studies (GWAS)4. The HLA region on 
chromosome 6 is by far the most significant, including the complement factor 4 locus5. Those common variants 
account for an estimated 23% of the total heritability, but each variant has only minor influence on the disease 
risk, with odds ratios typically below 1.103,4. Copy number variants (CNVs) constitute another major type of 
genetic susceptibility. Such CNVs are rare and may be recurrent (e.g., loci on 1q21.1, 2p16.3 (NRXN1), 3q29, 
7q11.2, 15q13.3, 16p11.2 proximal, 16p11.2 distal, and 22q11.2), usually leading to markedly increased risk of 
schizophrenia in addition to several neuropsychiatric conditions6–9. Finally, it has been shown that schizophrenia 
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is also associated with inherited, ultra-rare gene-disrupting and putatively protein-damaging variants, mainly in 
neuron-expressed genes that encode synaptic proteins10.
Despite these important findings, there is still a large gap between the estimated and explained heritability. 
Alternative approaches are therefore needed to identify more of the genetic factors, and one possibility is to focus 
on hypotheses driven by the pathophysiology of schizophrenia. Several structural MRI studies including diffu-
sion tensor imaging (DTI) have observed reduced white matter volume and changes in the fibre tracts in patients 
with schizophrenia11–13. Other studies have demonstrated reduced expression of myelination-related genes in 
post-mortem brain samples14–16. These data suggest that myelination abnormalities could be implicated in schiz-
ophrenia. Myelin is a multi-lamellar structure that wraps around the axons of the neurons. In the central nervous 
system (CNS), it is formed by the lipid-rich membrane of oligodendrocytes. The myelination process is complex 
and temporal, involving specification and proliferation of oligodendrocyte precursor cells (OPCs), differentiation 
of mature oligodendrocytes, with subsequent synthesis and turnover of structural myelin components including 
specialized proteins and lipids17,18. Previously, genes implicated in glial functions (astrocytes and oligodendro-
cytes) have been associated with schizophrenia when tested in gene enrichment analyses19–24. The aim of this 
study was to test more specifically the implication of genes related to myelination as a risk factor for schizophre-
nia, using a combination of common and rare variants in GWAS, exome chip and exome sequencing data.
Material and Methods
Generation of CNS myelin-related gene set. The CNS myelin-related gene set was generated in a two-
step process. First, we queried the Gene Ontology (GO) Consortium database (geneontology.org) by the search 
terms “myelin” and “myelination”, which gave a large number of GO terms, including “myelination” (436 gene 
products), “myelin sheath” (214 gene products), “regulation of myelination” (73 gene products), and “central 
nervous system myelination” (67 gene products). Due to the hierarchical tree structure of the GO database, more 
specific GO terms with fewer genes were in general contained within the broader terms “myelination” and “mye-
lin sheath”. Since the GO databases may be biased by research focus, and may include both type I and type II 
errors25,26, the different gene lists were manually curated to select genes with an biologically well-established link 
to myelin and myelination in the CNS, by careful review of the literature, similar to the approach of Devor et al.27. 
This enables exclusion of genes with weak documentation of the annotation or functional link to myelin in the 
peripheral nervous system only. In addition, we included a selection of genes that are involved in lipid biosyn-
thesis and transport (due to the role of lipids in myelination) or in monogenic disorders with structural myelin 
defects.
The complete CNS myelin-related gene set included a total of 117 genes - 113 protein-coding genes, 2 miRNA, 
1 lincRNA and 1 antisense gene (see Supplementary File 1), which was subdivided into genes with biologically 
known involvement in (1) oligodendrocyte precursor cell (OPC) specification and proliferation (N = 13 genes), 
(2) oligodendrocyte differentiation and myelination (N = 49 genes; including structural CNS myelin proteins), 
(3) lipid biosynthesis and transport (N = 29 genes) and (4) various other genes involved in myelination and 
myelin-related disorders (N = 26 genes).
Clinical samples. The CNS myelin-related gene set was queried in three different samples: (1) a multicenter 
GWAS sample of 35,476 schizophrenia cases and 46,839 controls from the Psychiatric Genetics Consortium 
(PGC SCZ2), (2) a Norwegian sample of 269 schizophrenia cases and 336 controls genotyped by the Illumina 
Exome chip, and (3) a Swedish sample of 2,527 schizophrenia cases and 2,536 controls that were exome sequenced 
(completely overlapping part of PGC SCZ2 for which we have access to raw data).
PGC schizophrenia GWAS samples. Summary statistics from the PGC-SCZ GWAS were downloaded from 
https://www.med.unc.edu/pgc/results-and-downloads. The data consist of summary statistics of 9,444,231 
imputed variants, on 35,476 cases and 46,839 controls from 46 cohorts of European ancestry (PGC SCZ2 discov-
ery set)4. SNPs with poor imputation (imputation score < 0.9) or minor allele frequencies < 0.1, ambiguous SNPs, 
and insertions/deletions were filtered out, leaving a total of 3,511,943 markers for analysis.
Norwegian exome chip-genotyped schizophrenia sample. The Norwegian sample consisted of 269 schizophrenia 
cases and 336 controls (605 unrelated individuals in total) from the TOP study28. All samples had been genotyped 
with the Illumina HumanExome Beadchip v1.0 array and re-analyzed from raw data using Illumina Genome 
Studio, according to the best practice from the CHARGE consortium29. Quality of called variants was improved 
using zCall30. Hardy-Weinberg equilibrium statistics of variants were tested by PLINK31. PLINK/SEQ was applied 
to transform accepted variants into a vcf file. 1,536 variants (MAF > 0) located within 117 myelination genes were 
extracted using VCFtools32. In 12 of these variants, the alternative allele was more frequent than the reference 
allele, so these variants were transposed to match hg19 reference.
Swedish exome sequenced schizophrenia sample. The Swedish sample consisted of 2,527 schizophrenia cases 
and 2,536 controls (5,063 unrelated individuals in total). All samples were sequenced using either the Agilent 
SureSelect Human All Exon Kit (29 Mb) or the Agilent SureSelect Human All Exon v.2 Kit (33 Mb) for exome 
capture33. Sequencing was performed by Illumina GAII or Illumina HiSeq2000. Sequence data were aligned 
and variants called by the Picard/BWA/GATK pipeline34. On the basis of Exome Chip data and validation of 
selected variants by Sanger sequencing, a high sensitivity and specificity of singleton calls was estimated as 
earlier described33. Variant frequencies are available in the dbGaP study phs000473.v1 (http://research.mssm.
edu/statgen/sweden). 4,766 variants located within 117 RefSeq defined myelination genes were extracted using 
VCFtools32. In 46 of these variants, the alternative allele was more frequent than the reference allele, so these var-
iants were transposed to match hg19 reference.
www.nature.com/scientificreports/
3SCIENTIfIC RePoRTS |  (2018) 8:6915  | DOI:10.1038/s41598-018-25280-4
Gene Set Enrichment Analysis (GSEA) in GWAS data. All SNPs in the PGC-SCZ GWAS data were 
annotated to known NCBI RefSeq genes (date: August 1, 2016)35. The list contained 27,063 genes; in case of sev-
eral variants, the longest was selected. Since the LD structure of the major histocompatibility complex (MHC) 
region is challenging, and genes from this region are overrepresented in SCZ GWAS, we excluded genes from 
hg19 chr6:25–34 Mb, with 26,730 genes remaining. SNPs were assigned to genes if they were a) located within the 
boundaries of the gene+/−10 kb upstream and downstream or if b) in LD (r2 ≥ 0.20) with another SNP located 
within the boundaries of the gene (+/−10 kb) using the LDsnpR tool36. For LD estimation, we used the European 
cohort from the 1000 Genomes Project37.
For each gene, a combined p-value score was calculated according to the Brown method38,39. The technique 
allows generation of combined p-value scores for dependent tests, where the correction procedure is based on 
the LD structure within the structural bin. The gene scores were log transformed and ranked in decreasing order.
The Gene Set Enrichment Analysis (GSEA)40 method was developed for global gene expression studies. 
However, this technique has also been used for GWAS studies41,42. The GSEA performs running sum statistics 
and calculates an enrichment score for each of the selected myelin-related genes, considering their rank in the 
pre-ranked gene list from the SCZ GWAS. The significance of the score was calculated using 1,500 permutations 
of the ranked list.
Analysis of common and rare variants in the exome sequence. Common variants (defined as minor 
allelic frequency > 0.1) in the 117 myelin-related genes were subject to case control association analysis, using all 
variants extracted from either the exome chip (Norwegian sample) and exome sequence (Swedish sample) data, 
as described above. Tests of association were performed using EPACTS single variant Logistic Score Test43, in 
accordance with the tool documentation.
Rare variants (defined as minor allelic frequency ≤ 0.1) extracted from the Norwegian and Swedish datasets 
were first analyzed for their potential differential clustering between cases and controls within certain genes (i.e. 
gene burden analysis), using the SKAT-O test44 according to the EPACTS tool documentation.
We also examined the total number of loci with rare variants per individual (both heterozygous and homozy-
gous, investigated separately) in the total set of 117 genes and the four subsets of genes in the Norwegian and 
Swedish samples. This analysis method is an approach to extend SKAT-O, which tests variant burden per gene. 
In contrast to SKAT-O, we test the burden of variants in groups of genes that are related to a certain function. The 
analysis was performed by reading vcf files into the R/Bioconductor environment, using the VariantAnnotation 
package45. Comparison of median values of variant counts were used to avoid influence of possible outliers. The 
difference in variant load between cases and controls was tested by Welch t-test.
Finally, loss of function (LoF) variants in the 117 myelin-related genes in the Swedish sample were annotated 
and selected using snpEff46 with -lof parameter. Their distribution in cases versus controls was tested with chi2 
test in R. We also counted the total number of LoF singleton variants and compared their distribution in cases 
versus controls.
Results
Lipid biosynthesis genes are associated to schizophrenia in schizophrenia GWAS data. As a 
first step, we sought to investigate the association of myelin gene groups with schizophrenia in the largest schizo-
phrenia GWAS dataset to date, PGC. The lowest p values for the myelination genes are provided in Supplementary 
File 1, with the most significant finding being p = 1.806 * 10−13 for rs115370182 (an intron variant in the MOG 
gene).
By using the publicly available PGC SCZ2 data, we performed a gene set enrichment analysis (GSEA) on the 
total myelination gene set (117 genes) as well as on the four subsets of genes (see Table 1). There was no significant 
enrichment for the myelination genes in total. One of the four subsets, the lipid biosynthesis and transport-related 
genes, demonstrated nominally significant enrichment of association to schizophrenia (p = 0.037), but this signal 
did not survive correction for multiple testing (FWER = 0.16). Moreover, further analysis of the subset revealed 
that SREBF1 and SREBF2 were ranked as no. 1 and 2 among the leading edge genes (Supplementary Table 1). 
Since both genes have previously been associated with schizophrenia47, the subgroup analysis was re-run after 









Myelination genes (total gene set) 117 0.49 1.16 0.072 0.072 0.072
Oligodendrocyte precursor cell (OPC) 
specification and proliferation (subset 1) 13 0.42 0.85 0.721 0.766 0.997
Oligodendrocyte differentiation and 
myelination (subset 2) 48 0.48 1.09 0.309 0.441 0.779
Lipid (incl. cholesterol) biosynthesis and 
transport (subset 3) 29 0.62 1.37 0.037 0.165 0.156
Other genes involved in myelination and 
myelin-related disorders (subset 4) 26 0.53 1.16 0.234 0.443 0.627
Table 1. Gene set enrichment analysis (GSEA) for myelin gene sets. The GSEA performs running sum statistics 
and calculates an enrichment score for each of the selected myelin-related genes, considering their rank in the 
pre-ranked gene list from the SCZ GWAS. The significance of the score was calculated using 1,500 permutations 
of the ranked list. Abbreviations: ES – enrichment score; NES – normalized enrichment score; NOM – nominal 
p-value; FDR – false discovery rate; FWER – family-wise error rate.
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exclusion of SREBF1 and SREBF2. The remaining subset of 27 genes failed to display any significant association 
(p = 0.32). No enrichment of association with schizophrenia was found for the three other gene subsets “OPC 
specification and proliferation”, “oligodendrocyte differentiation and myelination”, and “other genes involved in 
myelination and myelin-related disorders” (Table 1).
No association with schizophrenia for neither common nor rare variants within the coding 
sequence of the myelination genes. The next step was to examine association of common variants 
located in myelination genes to schizophrenia (analysis design provided in Supplementary File 2). We had access 
to a Norwegian sample of 269 schizophrenia cases and 336 controls (605 unrelated subjects in total) that had 
been genotyped with the Illumina Human Exome array, and a Swedish sample of 2,527 schizophrenia cases and 
2,536 controls (5,063 unrelated individuals in total) that had been exome sequenced. We observed a total of 
1,536 and 4,766 different variants within the 113 protein-coding and 4 non-coding myelination-related genes 
in the Norwegian and Swedish sample, respectively, including 185 and 187 common variants in the two samples 
(defined as MAF > 0.1). By logistic regression analysis of each common variant, we found no significant differ-
ences between cases and controls that survived correction for multiple testing (EPACTS, 5 * 10−8), with the lowest 
nominal p-value being 1.8 × 10−3 in Swedish data set (Fig. 1 and Table 2, Supplementary Files 3 and 4).
To test for accumulation of rare variants within a gene, we performed a gene burden analysis with SKAT-O. 
Differences between cases and controls in the Norwegian (lowest p-value 0.03; EIF4G44) and Swedish samples 
(lowest p-value 0.012; LPR1) (Table 2) did not survive correction for multiple testing. Detailed information of the 
SKAT-O gene burden analysis is provided in Supplementary Files 5 and 6.
In theory, a combination of variants in several myelination genes in the same subject could impose increased 
risk. We therefore examined the load of such variants in cases and controls with respect to the total gene set 
and each of the four subsets. We measured variant load by calculating cumulative number of heterozygous and 
homozygous variants. We observed a small difference between cases and controls in the median number of hete-
rozygous variants per subject for all myelination genes in the Swedish sample, but the p-value was not significant 
after correction for multiple testing (74 in cases versus 75 in controls; t-test p = 0.03; q = 0.30; Fig. 2). For the 
subset of “other genes involved in myelination and myelin-related disorders” in the Norwegian sample (10 in 
cases versus 9 in controls; p = 0.007) (Table 2). These differences were minor and none of them were supported 
by merged data from both samples.
No excess of loss-of-function variants in the myelination genes. In a final step of the analysis, we 
approached all loss-of-function (LoF) variants, defined as nonsense, frame shift (indels), splice gain and splice 
loss mutations. Due to a low number of such variants in the Norwegian sample (6 in total), we only used the 
Swedish dataset that contained 99 different LoF variants across all individuals, including 73 ultra-rare singletons 
(38 observed in the group of 2,527 schizophrenia patients and 33 among the 2,536 controls; p = 0.55) (Table 2). 
The remaining 28 non-singleton LoF variants were checked for differences between cases and controls, of which 
a heterozygous variant in PADI2 (stop gain; allele frequency 0.0015 in gnomAD database) had the lowest p value 
(chi square test; OR = 0.37, p = 0.03), but the p-value did not survive correction for multiple testing (Table 2).
Figure 1. Manhattan plots for common (MAF > 0.05) variants in Norwegian (A) and Swedish (B) cohorts. 
Variants located in myelination genes do not reach genome-wide significance.
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Discussion
In the current study, we examined the role of common and rare variants in myelination-related genes as risk 
factors for schizophrenia, using a combination of GWAS, exome chip and exome sequencing data in differ-
ent case control samples. We observed a nominally significant enrichment of common SNPs in a subset of 
lipogenesis-related genes in schizophrenia patients (p = 0.037), but conservative correction for multiple testing 
rejected this finding (FWER = 0.16). Moreover, the trend signal observed in this subset was mainly driven by 
variants in the well-known schizophrenia-associated genes SREBF1 and SREBF2.
Indeed, SREBF1 and SREBF2, encoding the SREBP1 and SREBP2 transcription factors that control fatty acid 
and cholesterol biosynthesis, were ranked as the two leading edge genes in the GSEA. Since SREBF1 and SREBF2 
on chromosome 17p11.2 and 22q13.2 have both been associated with schizophrenia4,48, the GSEA analysis of 
the PGC2 schizophrenia GWAS data was re-run after exclusion of these genes. The remaining subset of 27 genes 
failed to display any significant findings, demonstrating that the signal of association was mainly driven by the 
SREBF gene loci. It remains to be clarified whether variants in SREBF1 and SREBF2 influence the risk of schizo-
phrenia through effects on lipid biosynthesis and myelination in the brain.
There was no significant enrichment in the PGC2 schizophrenia GWAS data for the total set of myelination 
genes or for any of the three other subsets of genes, thereby excluding a major role of common SNPs in these 
Norwegian Sample Swedish Sample
N, schizophrenia patients/healthy controls 269/336 2,527/2,536
Genotyping platform Illumina HumanExome Beadchip v1.0 Illumina Exome Sequencing
SNPs and indels in myelination-related gene set 1,536 (1,532 with correct reference
4, with 
reversed reference and variant allele)
4,766 (4,720 with correct reference46, with 
reversed reference and variant allele)






- heterozygous 50 49 0.28 74 75 0.03
- homozygous alternative 11 11 0.85 20 20 0.87
Subset 1: Oligodendrocyte precursor cell 





- heterozygous 8 8 0.72 7 7 0.81
- homozygous alternative 2 2 0.78 1 2 0.6






- heterozygous 20 20 0.76 25 25 0.1
- homozygous alternative 4 5 0.79 9 9 0.58
Subset 3: Lipid (including cholesterol) biosynthesis 





- heterozygous 11 12 0.32 21 21 0.38
- homozygous alternative 3 3 0.71 5 5 0.77
Subset 4: Other genes involved in myelination and 





- heterozygous 10 9 0.007 22 22 0.09
- homozygous alternative 2 2 0.84 4 4 0.77
Common variants tested (MAF > 0.1) 185 187
Most significant common variants p = 0,037 p = 0,0018
Lowest p-value - Logistic Score 3:39523003_A/G_Intron:MOBP 2:198362018_T/C Synonymous: HSPD1
Test - single variant association AF SCZ: 0.76, AF CTR: 0.71 AF SCZ: 0.66 AF CTR:0.63
Most significant rare variant gene 0,03 0,012
Lowest p-value - SKAT-O Test - gene burden 
association for rare variants chr3:184035172-184049550_EIF4G1 chr12:57532238-57606021_LRP1
Loss of function (LOF) variants in the data set 6 99
Loss of Function variants (not singletons), lowest 
p-value
Not evaluated (array technology/
insufficient sample number for reliable 
analysis)
Schizophrenia: Control: chi2 p- value:
PADI2 chr1:17410253, heterozygous 7 18 0.03
NPC2 chr14:74947404 heterozygous 22 16 0.32
LOF singletons (present in one individual only)
Not evaluated (array technology/






38 33 p = 0.38
Table 2. Overview of the distribution of common and rare variants in myelination-related genes in 
schizophrenia patients and healthy controls. Table summarizes variant load per subject, single variant 
association, gene burden association and loss of function variant analysis. T-test and chi2 test values were 
computed in R. Significant differences are marked with bold font, however they did not survive correction for 
multiple testing (q > 0.05).
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genes as disease susceptibility factors. This result is in line with a study by Goudriaan et al.19 who reported an 
association between schizophrenia and lipid metabolism genes in the PGC1 GWAS data, but no significant find-
ings for a set of 17 myelination genes.
We also examined coding variants in the myelination genes, using exome chip and exome sequencing data. In 
general, the analyses of single variants, gene burden effects (i.e. number of variants within one gene) and variant 
load per subject (i.e. accumulation of variants in several genes in one person) did not display any statistically 
significant associations that survived correction for multiple testing. It is therefore unlikely that coding variants 
in the myelination-related genes play any major role as risk factors for schizophrenia. This is supported by the 
recent finding that the increased burden of ultra-rare, gene-disruptive variants in schizophrenia is mostly related 
to variants in neuronally expressed genes that encode proteins with synaptic localization10. It should be noted that 
the Swedish exome sequence data used by us overlap with the latter report.
The main strength of our study is the combination of a hypothesis-driven approach, a manually curated set 
of myelination-related genes and the analysis of both common and rare variants in different samples. The main 
weakness is the limited statistical power to detect associations between rare variants and schizophrenia, thereby 
lowering the value of the negative findings.
In conclusion, we have confirmed that non-coding variants linked to the SREBF1 and SREBF2 genes are asso-
ciated with increased risk of schizophrenia. Our data show that variants located within other myelination related 
genes are unlikely to be major susceptibility factors in schizophrenia.
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